Psychedelic Therapy FAQ: Honest Answers for the Educated Seeker

Is psychedelic therapy the same as recreational drug use?

No. The clinical model is structurally different from recreational use in every meaningful way: set, setting, dosing precision, pre-session screening, trained professional support, and structured integration afterward. Recreational use involves none of these elements. In clinical and professionally supported settings, the experience is designed to serve a defined psychological objective, with a guide present throughout.

Is psychedelic therapy safe?

This is the question that deserves the most honest answer. Psilocybin has a well-documented physiological safety profile: it is not considered toxic to organs at therapeutic doses, and it carries no known potential for physical dependence. A 2025 systematic review published in the Australian and New Zealand Journal of Psychiatry (Freitas et al., doi: 10.1177/00048674241289024) evaluated adverse event data across clinical trials of psilocybin-assisted psychotherapy and found that serious adverse events were rare and typically transient. The more significant risks are psychological: anxiety, disorientation, and emotional difficulty during the session, particularly in people with a personal or family history of psychosis or bipolar I disorder. Contraindications are real, and a qualified screening process is not optional. That screening process is the foundation of the concierge model JourneyOM uses.

What conditions is psychedelic therapy being studied for?

The most advanced research is in treatment-resistant depression and major depressive disorder. A 2026 randomized clinical trial published in JAMA Psychiatry (the EPISODE trial, Mertens et al.) found that psilocybin 25mg with adjunct psychotherapy produced significant treatment response in participants with treatment-resistant major depression. Beyond depression, active clinical trials are studying psilocybin for anxiety, OCD, PTSD, addiction, and end-of-life distress. The evidence base is growing quickly, though it is still early for several of these indications. This is where things get more nuanced: strong preliminary results do not automatically translate to approved treatments, and anyone who tells you otherwise is not being straight with you.

How long does a psilocybin session last?

A dosing session typically runs six to eight hours. This is not a quick intervention. Add preparation sessions beforehand (typically one to three meetings to establish goals, review contraindications, and build a working relationship with your guide), plus two to four integration sessions afterward. A complete, properly structured process commonly spans four to six weeks from first contact through final integration.

What is the role of a guide?

A guide (also called a facilitator in regulated state programs) is a trained professional who provides support before, during, and after a psychedelic experience. They do not direct or interpret the experience for you. Their function is to establish safety, support emotional processing if difficulty arises during the session, and help you extract durable meaning from the experience in integration work afterward. The quality and training of the guide is one of the strongest predictors of outcome in the clinical literature.

What does “professionally supported” mean in practice?

It means the entire arc of your experience is structured around clinical best practices, with qualified personnel involved at each stage: intake, screening, preparation, the dosing session itself, and integration. A concierge model like JourneyOM’s adds another layer: matching you to a guide whose background, approach, and experience actually fit your situation, rather than simply connecting you to whoever is available.

Is psychedelic therapy legal?

In the United States, psilocybin remains a Schedule I controlled substance at the federal level. State law is a different picture. Oregon established licensed psilocybin service centers through Measure 109, with programs operating since 2023. Colorado legalized psilocybin through Proposition 122 in 2022, with licensed healing centers opening in 2025. New Mexico signed its Medical Psilocybin Act into law in April 2025, making it the third state with a legal regulated framework. Internationally, Australia, Canada, and several European countries offer access under varying medical frameworks. The patchwork is complex and evolving rapidly. Jurisdiction matters significantly when determining what is legally available to you.

What does psychedelic therapy cost?

In Oregon’s licensed market, a single therapeutic session runs from roughly $1,000 to $3,500 or more, with the total cost of a complete program including preparation and integration running higher. As of mid-2025, Health Affairs reported that the average client at an Oregon psilocybin clinic earns around $164,000 annually, reflecting the current access gap. Insurance coverage remains largely unavailable for psilocybin-assisted therapy, though the cost-effectiveness research is building. This is a real limitation of the current landscape, and no credible provider will tell you otherwise.

Will my insurance cover it?

For psilocybin-assisted therapy, almost certainly not at this stage. Coverage is more available for ketamine-based treatments in some cases, as ketamine is FDA-approved for treatment-resistant depression and some insurers cover it under certain conditions. The insurance landscape for psychedelic therapy is expected to evolve as clinical evidence accumulates and regulatory frameworks solidify, but current access is primarily out-of-pocket.

Who should not consider psychedelic therapy?

Standard contraindications include a personal or family history of schizophrenia, schizoaffective disorder, or bipolar I disorder; current use of certain medications including lithium and some antidepressants that may interact with serotonergic compounds; active cardiovascular conditions; and pregnancy. This list is not exhaustive. A medically informed screening process is mandatory before any responsible engagement with psychedelic-assisted approaches. If a provider skips the screening, that is a disqualifying sign.

What are the psychological risks?

The most common adverse effects reported in clinical trials are transient: anxiety, confusion, and emotional intensity during the session. Persistent adverse effects are less common but documented, including prolonged anxiety, difficulty integrating the experience, and in rare cases a phenomenon called HPPD (hallucinogen persisting perception disorder). The risk profile shifts significantly with adequate preparation, a stable psychological baseline, a skilled guide, and structured integration. Context is not incidental to safety; it is central to it.

How do I find a qualified guide?

This is where the market is genuinely uneven. Regulatory frameworks in Oregon and Colorado require facilitators to complete accredited training programs, but outside those jurisdictions, credentialing standards vary widely. Key things to look for: documented training from an accredited program, supervised clinical hours, a transparent screening and intake process, and a clear integration protocol. A guide who cannot articulate their methodology clearly, or who minimizes risk during an initial consultation, warrants caution.

What is integration, and why does it matter?

Integration is the process of working through and applying what emerged during a psychedelic experience. Research consistently indicates that the experience itself is not the endpoint: the durable psychological changes associated with psychedelic therapy are largely mediated by what happens in the weeks following the session. Integration typically involves one-on-one sessions with a therapist or guide, journaling, and in some cases complementary practices such as somatic work or mindfulness. Skipping integration is one of the most common ways a potentially valuable experience fails to translate into lasting benefit.

What about confidentiality and privacy?

This is a legitimate concern, particularly for executives and professionals in regulated industries. In jurisdictions where psilocybin therapy is legal and conducted through licensed providers, standard clinical confidentiality protections apply. Outside of those frameworks, the confidentiality picture is considerably less structured. Any provider you work with should be able to clearly explain how your health information is handled, stored, and protected. This question is worth asking directly and early.

How is this different from ketamine therapy?

Ketamine is a dissociative anesthetic rather than a classical psychedelic. It is FDA-approved (as esketamine/Spravato) for treatment-resistant depression and is available through licensed medical providers in all US states. Its mechanism of action targets glutamate pathways rather than serotonin. Effects are shorter in duration (typically 40 to 90 minutes per session) and the treatment model often involves repeated sessions. Psilocybin works through 5-HT2A serotonin receptor agonism, produces a longer-duration experience, and in clinical trials has shown sustained antidepressant effects from one or two sessions. They are complementary options with different profiles, not direct substitutes.  Read more about Ketamine vs. Esketamine (Spravato) and Psilocybin vs. Ketamine.

What outcomes should I realistically expect?

Current clinical data suggests that a significant proportion of participants in psilocybin trials for depression experience meaningful symptom reduction, with some evidence of effects persisting at six and twelve months following treatment. A systematic review in Frontiers in Psychiatry (2024) found substantial antidepressant effects in multiple randomized controlled trials, with some open-label studies reporting effects persisting for at least twelve months. These are not small effect sizes by psychiatric standards. However, response is not universal, the research population differs from the general population, and outcomes depend heavily on preparation, guide quality, and integration. Managing expectations without dismissing genuine potential is the appropriate stance.

Can psychedelic therapy improve cognitive performance or resilience?

This is an area of active investigation rather than established science. Some researchers are examining psilocybin’s effects on neuroplasticity, default mode network activity, and psychological flexibility. Preliminary data is interesting, but translating neuroimaging findings into claims about executive performance or resilience is premature. What the clinical evidence does support is meaningful reduction in symptoms of depression, anxiety, and existential distress, which are themselves barriers to functioning at a high level. The performance framing may prove accurate over time; it is not yet the established claim.

How do I start?

The first step is an honest assessment of whether you are an appropriate candidate: health history, current medications, psychological baseline, and realistic goals. That assessment should happen before any decisions about when, where, or with whom. A qualified intake conversation, at no cost or low cost, is the right starting point. It is also where a concierge model earns its value: matching you to the right guide and the right approach before committing to a program.